How  ||| S:0 E:4 ||| WRB
immunotherapy  ||| S:4 E:18 ||| NNS
can  ||| S:18 E:22 ||| MD
enhance  ||| S:22 E:30 ||| VB
the  ||| S:30 E:34 ||| DT
response  ||| S:34 E:43 ||| NN
to  ||| S:43 E:46 ||| TO
other  ||| S:46 E:52 ||| JJ
modalities  ||| S:52 E:63 ||| NN
and  ||| S:63 E:67 ||| CC
improve  ||| S:67 E:75 ||| VB
outcome  ||| S:75 E:83 ||| NN
and  ||| S:83 E:87 ||| CC
quality  ||| S:87 E:95 ||| NN
of  ||| S:95 E:98 ||| IN
life  ||| S:98 E:103 ||| NN
Early  ||| S:103 E:109 ||| RB
studies  ||| S:109 E:117 ||| VBZ
suggested  ||| S:117 E:127 ||| VBN
that  ||| S:127 E:132 ||| IN
the  ||| S:132 E:136 ||| DT
induction  ||| S:136 E:146 ||| NN
of  ||| S:146 E:149 ||| IN
an  ||| S:149 E:152 ||| DT
effective  ||| S:152 E:162 ||| JJ
immune  ||| S:162 E:169 ||| JJ
response  ||| S:169 E:178 ||| NN
could  ||| S:178 E:184 ||| MD
lead  ||| S:184 E:189 ||| VB
to  ||| S:189 E:192 ||| TO
elimination  ||| S:192 E:204 ||| NN
of  ||| S:204 E:207 ||| IN
residual  ||| S:207 E:216 ||| JJ
tumour ||| S:216 E:222 ||| NN
.  ||| S:222 E:224 ||| .
Over  ||| S:224 E:229 ||| IN
a  ||| S:229 E:231 ||| DT
hundred  ||| S:231 E:239 ||| CD
years  ||| S:239 E:245 ||| NNS
ago  ||| S:245 E:249 ||| IN
Coley  ||| S:249 E:255 ||| NNP
invented  ||| S:255 E:264 ||| VBD
his  ||| S:264 E:268 ||| PRP$
eponymous  ||| S:268 E:278 ||| NNS
named  ||| S:278 E:284 ||| VBN
toxins  ||| S:284 E:291 ||| NNS
that  ||| S:291 E:296 ||| WDT
appeared  ||| S:296 E:305 ||| VBD
to  ||| S:305 E:308 ||| TO
induce  ||| S:308 E:315 ||| VB
a  ||| S:315 E:317 ||| DT
strong  ||| S:317 E:324 ||| JJ
inflammatory  ||| S:324 E:337 ||| JJ
response ||| S:337 E:345 ||| NN
,  ||| S:345 E:347 ||| ,
leading  ||| S:347 E:355 ||| VBG
to  ||| S:355 E:358 ||| TO
tumour  ||| S:358 E:365 ||| VB
reduction ||| S:365 E:374 ||| NN
.  ||| S:374 E:376 ||| .
Subsequent  ||| S:376 E:387 ||| JJ
attempts  ||| S:387 E:396 ||| NNS
to  ||| S:396 E:399 ||| TO
enhance  ||| S:399 E:407 ||| VB
the  ||| S:407 E:411 ||| DT
immune  ||| S:411 E:418 ||| JJ
response  ||| S:418 E:427 ||| NN
have  ||| S:427 E:432 ||| VBP
essentially  ||| S:432 E:444 ||| RB
been  ||| S:444 E:449 ||| VBN
on  ||| S:449 E:452 ||| IN
a  ||| S:452 E:454 ||| DT
vaccine  ||| S:454 E:462 ||| NN
basis ||| S:462 E:467 ||| NN
,  ||| S:467 E:469 ||| ,
trying  ||| S:469 E:476 ||| VBG
to  ||| S:476 E:479 ||| TO
induce  ||| S:479 E:486 ||| VB
a  ||| S:486 E:488 ||| DT
specific  ||| S:488 E:497 ||| JJ
response  ||| S:497 E:506 ||| NN
against  ||| S:506 E:514 ||| IN
the  ||| S:514 E:518 ||| DT
tumour ||| S:518 E:524 ||| NN
.  ||| S:524 E:526 ||| .
Numerous  ||| S:526 E:535 ||| JJ
vaccine  ||| S:535 E:543 ||| NN
approaches  ||| S:543 E:554 ||| NNS
have  ||| S:554 E:559 ||| VBP
claimed  ||| S:559 E:567 ||| VBN
to  ||| S:567 E:570 ||| TO
give  ||| S:570 E:575 ||| VB
significant  ||| S:575 E:587 ||| JJ
clinical  ||| S:587 E:596 ||| JJ
benefit  ||| S:596 E:604 ||| NN
in  ||| S:604 E:607 ||| IN
clinical  ||| S:607 E:616 ||| JJ
response  ||| S:616 E:625 ||| NN
but  ||| S:625 E:629 ||| CC
very  ||| S:629 E:634 ||| RB
few  ||| S:634 E:638 ||| JJ
of  ||| S:638 E:641 ||| IN
these  ||| S:641 E:647 ||| DT
have  ||| S:647 E:652 ||| VBP
survived  ||| S:652 E:661 ||| VBN
a  ||| S:661 E:663 ||| DT
randomised  ||| S:663 E:674 ||| JJ
trial ||| S:674 E:679 ||| NN
.  ||| S:679 E:681 ||| .
A  ||| S:681 E:683 ||| DT
major  ||| S:683 E:689 ||| JJ
reason  ||| S:689 E:696 ||| NN
for  ||| S:696 E:700 ||| IN
this  ||| S:700 E:705 ||| DT
is  ||| S:705 E:708 ||| VBZ
the  ||| S:708 E:712 ||| DT
heterogeneity  ||| S:712 E:726 ||| NN
of  ||| S:726 E:729 ||| IN
many  ||| S:729 E:734 ||| JJ
tumours ||| S:734 E:741 ||| NN
,  ||| S:741 E:743 ||| ,
as  ||| S:743 E:746 ||| RB
well  ||| S:746 E:751 ||| RB
as  ||| S:751 E:754 ||| IN
the  ||| S:754 E:758 ||| DT
various  ||| S:758 E:766 ||| JJ
forms  ||| S:766 E:772 ||| NNS
of  ||| S:772 E:775 ||| IN
defence  ||| S:775 E:783 ||| NN
against  ||| S:783 E:791 ||| IN
an  ||| S:791 E:794 ||| DT
immune  ||| S:794 E:801 ||| JJ
response  ||| S:801 E:810 ||| NN
that  ||| S:810 E:815 ||| IN
they  ||| S:815 E:820 ||| PRP
employ ||| S:820 E:826 ||| VBP
.  ||| S:826 E:828 ||| .
It  ||| S:828 E:831 ||| PRP
was  ||| S:831 E:835 ||| VBD
thought  ||| S:835 E:843 ||| VBN
that  ||| S:843 E:848 ||| IN
chemotherapy  ||| S:848 E:861 ||| NN
and  ||| S:861 E:865 ||| CC
radiotherapy  ||| S:865 E:878 ||| NNS
were  ||| S:878 E:883 ||| VBD
mutually  ||| S:883 E:892 ||| RB
exclusive  ||| S:892 E:902 ||| JJ
for  ||| S:902 E:906 ||| IN
immunotherapy  ||| S:906 E:920 ||| NNS
using  ||| S:920 E:926 ||| VBG
the  ||| S:926 E:930 ||| DT
vaccine  ||| S:930 E:938 ||| NN
approach ||| S:938 E:946 ||| NN
.  ||| S:946 E:948 ||| .
More  ||| S:948 E:953 ||| RBR
recently ||| S:953 E:961 ||| RB
,  ||| S:961 E:963 ||| ,
however ||| S:963 E:970 ||| RB
,  ||| S:970 E:972 ||| ,
it  ||| S:972 E:975 ||| PRP
has  ||| S:975 E:979 ||| VBZ
become  ||| S:979 E:986 ||| VBN
appreciated  ||| S:986 E:998 ||| VBN
that  ||| S:998 E:1003 ||| IN
vaccine  ||| S:1003 E:1011 ||| NN
approaches  ||| S:1011 E:1022 ||| NNS
may  ||| S:1022 E:1026 ||| MD
enhance  ||| S:1026 E:1034 ||| VB
subsequent  ||| S:1034 E:1045 ||| JJ
responses  ||| S:1045 E:1055 ||| NNS
to  ||| S:1055 E:1058 ||| TO
radiotherapy  ||| S:1058 E:1071 ||| VB
and  ||| S:1071 E:1075 ||| CC
that  ||| S:1075 E:1080 ||| DT
certain  ||| S:1080 E:1088 ||| JJ
chemotherapies  ||| S:1088 E:1103 ||| NNS
actually  ||| S:1103 E:1112 ||| RB
enhance  ||| S:1112 E:1120 ||| VB
responses  ||| S:1120 E:1130 ||| NNS
to  ||| S:1130 E:1133 ||| TO
vaccines ||| S:1133 E:1141 ||| NNS
.  ||| S:1141 E:1143 ||| .
It  ||| S:1143 E:1146 ||| PRP
has  ||| S:1146 E:1150 ||| VBZ
been  ||| S:1150 E:1155 ||| VBN
suggested  ||| S:1155 E:1165 ||| VBN
that  ||| S:1165 E:1170 ||| IN
one  ||| S:1170 E:1174 ||| CD
of  ||| S:1174 E:1177 ||| IN
the  ||| S:1177 E:1181 ||| DT
mechanisms  ||| S:1181 E:1192 ||| NNS
of  ||| S:1192 E:1195 ||| IN
action  ||| S:1195 E:1202 ||| NN
of  ||| S:1202 E:1205 ||| IN
chemotherapy  ||| S:1205 E:1218 ||| NN
is  ||| S:1218 E:1221 ||| VBZ
to  ||| S:1221 E:1224 ||| TO
reduce  ||| S:1224 E:1231 ||| VB
the  ||| S:1231 E:1235 ||| DT
cells  ||| S:1235 E:1241 ||| NNS
that  ||| S:1241 E:1246 ||| IN
suppress  ||| S:1246 E:1255 ||| JJ
T-cells ||| S:1255 E:1262 ||| NN
.  ||| S:1262 E:1264 ||| .
These  ||| S:1264 E:1270 ||| DT
cells  ||| S:1270 E:1276 ||| NNS
primarily  ||| S:1276 E:1286 ||| RB
defend  ||| S:1286 E:1293 ||| VB
the  ||| S:1293 E:1297 ||| DT
tumour  ||| S:1297 E:1304 ||| NN
from  ||| S:1304 E:1309 ||| IN
an  ||| S:1309 E:1312 ||| DT
immunological  ||| S:1312 E:1326 ||| JJ
attack ||| S:1326 E:1332 ||| NN
,  ||| S:1332 E:1334 ||| ,
but  ||| S:1334 E:1338 ||| CC
more  ||| S:1338 E:1343 ||| RBR
recently  ||| S:1343 E:1352 ||| RB
it  ||| S:1352 E:1355 ||| PRP
has  ||| S:1355 E:1359 ||| VBZ
been  ||| S:1359 E:1364 ||| VBN
suggested  ||| S:1364 E:1374 ||| VBN
that  ||| S:1374 E:1379 ||| IN
the  ||| S:1379 E:1383 ||| DT
benefit  ||| S:1383 E:1391 ||| NN
may  ||| S:1391 E:1395 ||| MD
encompass  ||| S:1395 E:1405 ||| VB
other  ||| S:1405 E:1411 ||| JJ
aspects ||| S:1411 E:1418 ||| NNS
,  ||| S:1418 E:1420 ||| ,
such  ||| S:1420 E:1425 ||| JJ
as  ||| S:1425 E:1428 ||| IN
enhancing  ||| S:1428 E:1438 ||| VBG
antiangiogenic  ||| S:1438 E:1453 ||| JJ
responses ||| S:1453 E:1462 ||| NNS
.  ||| S:1462 E:1464 ||| .
One  ||| S:1464 E:1468 ||| CD
reason  ||| S:1468 E:1475 ||| NN
why  ||| S:1475 E:1479 ||| WRB
immunostimulatory  ||| S:1479 E:1497 ||| JJ
approaches  ||| S:1497 E:1508 ||| NNS
may  ||| S:1508 E:1512 ||| MD
be  ||| S:1512 E:1515 ||| VB
so  ||| S:1515 E:1518 ||| RB
useful  ||| S:1518 E:1525 ||| JJ
in  ||| S:1525 E:1528 ||| IN
cancer  ||| S:1528 E:1535 ||| NN
is  ||| S:1535 E:1538 ||| VBZ
that  ||| S:1538 E:1543 ||| DT
many  ||| S:1543 E:1548 ||| JJ
cancers  ||| S:1548 E:1556 ||| NNS
evolve  ||| S:1556 E:1563 ||| VB
out  ||| S:1563 E:1567 ||| RP
of  ||| S:1567 E:1570 ||| IN
a  ||| S:1570 E:1572 ||| DT
chronic  ||| S:1572 E:1580 ||| JJ
inflammatory  ||| S:1580 E:1593 ||| JJ
environment  ||| S:1593 E:1605 ||| NN
that  ||| S:1605 E:1610 ||| WDT
actively  ||| S:1610 E:1619 ||| RB
suppresses  ||| S:1619 E:1630 ||| JJ
cell  ||| S:1630 E:1635 ||| NN
mediated  ||| S:1635 E:1644 ||| VBZ
immune  ||| S:1644 E:1651 ||| JJ
responses  ||| S:1651 E:1661 ||| NNS
and  ||| S:1661 E:1665 ||| CC
enhances  ||| S:1665 E:1674 ||| VBZ
tumour  ||| S:1674 E:1681 ||| JJ
angiogenesis ||| S:1681 E:1693 ||| NN
.  ||| S:1693 E:1695 ||| .
An  ||| S:1695 E:1698 ||| DT
ideal  ||| S:1698 E:1704 ||| JJ
cancer  ||| S:1704 E:1711 ||| NN
drug  ||| S:1711 E:1716 ||| NN
would  ||| S:1716 E:1722 ||| MD
therefore  ||| S:1722 E:1732 ||| RB
be  ||| S:1732 E:1735 ||| VB
expected  ||| S:1735 E:1744 ||| VBN
to  ||| S:1744 E:1747 ||| TO
have  ||| S:1747 E:1752 ||| VB
these  ||| S:1752 E:1758 ||| DT
properties ||| S:1758 E:1768 ||| NNS
.  ||| S:1768 E:1770 ||| .
One  ||| S:1770 E:1774 ||| CD
such  ||| S:1774 E:1779 ||| JJ
drug  ||| S:1779 E:1784 ||| NN
is  ||| S:1784 E:1787 ||| VBZ
lenalidomide ||| S:1787 E:1799 ||| VBN
,  ||| S:1799 E:1801 ||| ,
which  ||| S:1801 E:1807 ||| WDT
features  ||| S:1807 E:1816 ||| NNS
include  ||| S:1816 E:1824 ||| VBP
marked  ||| S:1824 E:1831 ||| VBN
immune  ||| S:1831 E:1838 ||| JJ
stimulatory  ||| S:1838 E:1850 ||| JJ
properties  ||| S:1850 E:1861 ||| NNS
as  ||| S:1861 E:1864 ||| IN
well  ||| S:1864 E:1869 ||| RB
being  ||| S:1869 E:1875 ||| VBG
able  ||| S:1875 E:1880 ||| JJ
to  ||| S:1880 E:1883 ||| TO
inhibit  ||| S:1883 E:1891 ||| VB
regulatory  ||| S:1891 E:1902 ||| JJ
T-cells ||| S:1902 E:1909 ||| NN
.  ||| S:1909 E:1911 ||| .
They  ||| S:1911 E:1916 ||| PRP
have  ||| S:1916 E:1921 ||| VBP
also  ||| S:1921 E:1926 ||| RB
been  ||| S:1926 E:1931 ||| VBN
shown  ||| S:1931 E:1937 ||| VBN
to  ||| S:1937 E:1940 ||| TO
enhance  ||| S:1940 E:1948 ||| VB
anticancer  ||| S:1948 E:1959 ||| JJ
activity  ||| S:1959 E:1968 ||| NN
with  ||| S:1968 E:1973 ||| IN
vaccines  ||| S:1973 E:1982 ||| NNS
in  ||| S:1982 E:1985 ||| IN
both  ||| S:1985 E:1990 ||| DT
preclinical  ||| S:1990 E:2002 ||| JJ
models  ||| S:2002 E:2009 ||| NNS
and  ||| S:2009 E:2013 ||| CC
more  ||| S:2013 E:2018 ||| RBR
recently  ||| S:2018 E:2027 ||| RB
in  ||| S:2027 E:2030 ||| IN
clinical  ||| S:2030 E:2039 ||| JJ
observations ||| S:2039 E:2051 ||| NNS
,  ||| S:2051 E:2053 ||| ,
where  ||| S:2053 E:2059 ||| WRB
the  ||| S:2059 E:2063 ||| DT
responses  ||| S:2063 E:2073 ||| NNS
to  ||| S:2073 E:2076 ||| TO
vaccines  ||| S:2076 E:2085 ||| VB
in  ||| S:2085 E:2088 ||| IN
patients  ||| S:2088 E:2097 ||| NNS
with  ||| S:2097 E:2102 ||| IN
myeloma  ||| S:2102 E:2110 ||| NN
is  ||| S:2110 E:2113 ||| VBZ
much  ||| S:2113 E:2118 ||| RB
higher  ||| S:2118 E:2125 ||| JJR
when  ||| S:2125 E:2130 ||| WRB
they  ||| S:2130 E:2135 ||| PRP
are  ||| S:2135 E:2139 ||| VBP
on  ||| S:2139 E:2142 ||| IN
lenalidomide  ||| S:2142 E:2155 ||| NN
than  ||| S:2155 E:2160 ||| IN
other  ||| S:2160 E:2166 ||| JJ
treatments ||| S:2166 E:2176 ||| NNS
.  ||| S:2176 E:2178 ||| .
A  ||| S:2178 E:2180 ||| DT
number  ||| S:2180 E:2187 ||| NN
of  ||| S:2187 E:2190 ||| IN
regularly  ||| S:2190 E:2200 ||| RB
used  ||| S:2200 E:2205 ||| VBN
chemotherapy  ||| S:2205 E:2218 ||| JJ
regimens  ||| S:2218 E:2227 ||| NNS
have  ||| S:2227 E:2232 ||| VBP
marked  ||| S:2232 E:2239 ||| VBN
activity  ||| S:2239 E:2248 ||| NN
in  ||| S:2248 E:2251 ||| IN
modulating  ||| S:2251 E:2262 ||| VBG
the  ||| S:2262 E:2266 ||| DT
immune  ||| S:2266 E:2273 ||| JJ
response ||| S:2273 E:2281 ||| NN
.  ||| S:2281 E:2283 ||| .
These  ||| S:2283 E:2289 ||| DT
maybe  ||| S:2289 E:2295 ||| RB
of  ||| S:2295 E:2298 ||| IN
benefit  ||| S:2298 E:2306 ||| NN
and  ||| S:2306 E:2310 ||| CC
the  ||| S:2310 E:2314 ||| DT
regimens  ||| S:2314 E:2323 ||| NN
will  ||| S:2323 E:2328 ||| MD
be  ||| S:2328 E:2331 ||| VB
reviewed ||| S:2331 E:2339 ||| VBN
,  ||| S:2339 E:2341 ||| ,
which  ||| S:2341 E:2347 ||| WDT
include  ||| S:2347 E:2355 ||| VBP
gemcitabine ||| S:2355 E:2366 ||| VBN
,  ||| S:2366 E:2368 ||| ,
cyclophosphamide  ||| S:2368 E:2385 ||| NN
and  ||| S:2385 E:2389 ||| CC
the  ||| S:2389 E:2393 ||| DT
IMiDs ||| S:2393 E:2398 ||| JJ
.  ||| S:2398 E:2400 ||| .
